Clinical trials: VITILIGO
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Vitiligo
Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.
Vitiligo is an autoimmune depigmentation disorder affecting 0.5 to 1% of the population worldwide. Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in…
- Trial name
- NCT06446063
- Testing
- Test product, Control Product
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Non-segmental Vitiligo
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it.
- Trial name
- NCT06113328
- Testing
- MK-6194
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 169 people
- Sponsor
- Merck Sharp & Dohme LLC
Vitiligo
Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
The purpose of this study is to assess the efficacy and safety of SHR0302 ointment in adult patients with Vitiligo.
- Trial name
- NCT04774809
- Testing
- Low Dose SHR0302 Ointment BID, High Dose SHR0302 Ointment BID
- Where
- 16 sites in China
- Volunteers
- 75 people
- Sponsor
- Reistone Biopharma Company Limited
Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial)…
- Trial name
- NCT05247489
- Testing
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Where
- 13 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Non-Segmental Vitiligo (NSV)
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe…
- Trial name
- NCT07889492
- Testing
- EB06
- Where
- 4 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Edesa Biotech Inc.
Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who…
- Trial name
- NCT04530344
- Testing
- ruxolitinib, Vehicle
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 458 people
- Sponsor
- Incyte Corporation
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie
Non-segmental Vitiligo
A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients
A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.
- Trial name
- NCT06511739
- Testing
- SYHX1901
- Where
- China
- Volunteers
- 144 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Visible Light Exposure on Healthy Back Skin
ANTIPIGMENTING OR DEPIMENTING EFFICACY UNDER PART OF VISIBLE LIGHT
The study intends to validate a protocol and define a positive reference to evaluate the efficacy of anti-pigmenting and depigmenting agents under part of visible Light exposures, between 400nm to 450nm.
- Trial name
- ACR_BIOVI_21-0 (NCT06945393)
- Testing
- Cosmetic topical products
- Where
- Romania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Non-segmental Vitiligo
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
- Trial name
- NCT04487860
- Testing
- AS012
- Where
- 31 sites in United States, India
- Volunteers
- 327 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata, Vitiligo
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
- Trial name
- NCT06602232
- Testing
- DR-01
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Dren Bio
Vitiligo
Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo
This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period.
- Trial name
- NCT07181187
- Testing
- MH004 Ointment, Vehicle Ointment
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)
The purpose of this study is to look at the efficacy of afamelanotide, when combined with narrow-band ultraviolet B (NB-UVB) light, in patients with nonsegmental vitiligo.
- Trial name
- CUV102 (NCT01430195)
- Testing
- Afamelanotide, Narrow-Band UVB Light Treatment
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Vitiligo
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
- Trial name
- NCT07682506
- Testing
- MH004 1.0% Ointment
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04057573
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 76 sites in United States, Bulgaria and 7 more
- Volunteers
- 344 people
- Sponsor
- Incyte Corporation
Vitiligo
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
- Trial name
- NCT03099304
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 26 sites in United States
- Volunteers
- 157 people
- Sponsor
- Incyte Corporation